Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study

BACKGROUND: Folfirinox (FFX) and gemcitabine/nab-paclitaxel (GN) are both standard first-line treatments in patients with metastatic pancreatic cancer (mPC). However, data comparing these two chemotherapeutic regimens and their sequential use remain scarce. METHODS: Data from two independent cohorts...

Descripción completa

Detalles Bibliográficos
Autores principales: Williet, Nicolas, Saint, Angélique, Pointet, Anne-Laure, Tougeron, David, Pernot, Simon, Pozet, Astrid, Bechade, Dominique, Trouilloud, Isabelle, Lourenco, Nelson, Hautefeuille, Vincent, Locher, Christophe, Desrame, Jérome, Artru, Pascal, Thirot Bidault, Anne, Le Roy, Bertrand, Pezet, Denis, Phelip, Jean-Marc, Taieb, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764033/
https://www.ncbi.nlm.nih.gov/pubmed/31598136
http://dx.doi.org/10.1177/1756284819878660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764033/
https://www.ncbi.nlm.nih.gov/pubmed/31598136
http://dx.doi.org/10.1177/1756284819878660

Ejemplares similares